Skip to content

The effect of mouthwash containing Zataria multiflora essence 2% on the prevention of ventilator-associated pneumonia

The comparative effects of the mouthwash containing Zataria multiflora essence 2% and chlorhexidine 0.2% on the prevention of ventilator-associated pneumonia in patients admitted to intensive care units

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT20210523051370N6
Enrollment
120
Registered
2022-05-21
Start date
2022-06-05
Completion date
Unknown
Last updated
2022-08-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ventilator-associated pneumonia. ventilator-associated pneumonia

Interventions

Intervention 1: Intervention group: The patient is assessed for pneumonia using the Clinical Pulmonary Infection Score (CPIS) before the mouthwash is administered. All the tooth surfaces and gum are c

Sponsors

Mazandaran University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Patients aged 18-65 years Having a tracheal tube <12 hours elapsed since ICU admission Having natural teeth

Exclusion criteria

Exclusion criteria: Patients with tracheostomy tube A history of taking antibiotics during the last two weeks A history of allergy to chlorhexidine and herbal mouthwashes Reintubation Severe maxillofacial trauma Cervical spine immobilization Pregnant and lactating women A history of malignancy and cancer A history of head and neck radiotherapy A history of oral mucositis and periodontal diseases Patients diagnosed with sepsis Patients with immune system disorders Patients with lung diseases (including pneumonia, asthma, and allergic rhinitis) Simultaneously participating in other interventional studies Patients with COVID-19 in admission Withdrawal criteria: patient death; patients transferred to the ward or other hospitals; reintubation; side effects associated with the use of either mouthwash; oral mucositis and periodontal diseases; sepsis; unwillingness to continue participation in the study; eligibility criteria violated

Design outcomes

Primary

MeasureTime frame
Clinical Pulmonary Infection Score. Timepoint: Clinical Pulmonary Infection Score on first, third and fifth days of mouthwash use. Method of measurement: Pulmonary of Infection Survey Questionnaire.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Seyed Afshin Shorofi

Mazandaran University of Medical Sciences

ashorofi@yahoo.com+98 11 3336 7342

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026